Close



Sep 28, 2022 08:27AM
Sep 26, 2022 04:11PM
Aug 30, 2022 02:53PM
Jul 28, 2022 01:32PM
Jul 20, 2022 05:50AM
Jul 13, 2022 06:18PM
Jul 13, 2022 07:44AM Cantor Fitzgerald Reiterates Neutral Rating, $1 Price Target on TherapeuticsMD (TXMD) on Failed Acquisition
Jul 13, 2022 06:38AM
Jul 13, 2022 06:36AM
Jul 7, 2022 06:15AM
Jun 22, 2022 05:44PM
Jun 7, 2022 05:36AM
Jun 6, 2022 08:41AM
Jun 6, 2022 06:27AM "Positive Zotatifin Data Supports An Opportunity In Breast Cancer" - Cantor Fitzgerald Bullish on eFFECTOR Therapeutics (EFTR) With Overweight Rating, $50 Price Target
Jun 2, 2022 05:54AM
Jun 1, 2022 05:35AM
May 24, 2022 08:21AM
May 24, 2022 06:00AM
May 17, 2022 06:48AM
May 17, 2022 06:13AM
May 16, 2022 09:49AM Cantor Fitzgerald Reiterates Overweight Rating. $15 Price Target on ContraFect (CFRX), "Expect Upwards Earnings Revision to Move Share Higher"
May 13, 2022 06:27AM
May 12, 2022 09:44AM
May 12, 2022 06:21AM
May 10, 2022 09:39AM
May 3, 2022 09:01AM
May 3, 2022 06:57AM
Apr 29, 2022 05:52AM UPDATE: Cantor Fitzgerald Starts Roivant Sciences (ROIV) at Overweight
Apr 19, 2022 07:37AM
Apr 12, 2022 08:16AM
Apr 11, 2022 06:23AM
Apr 8, 2022 06:09AM
Apr 7, 2022 09:08AM
Apr 7, 2022 06:19AM
Apr 5, 2022 01:28PM Merck's "Growth Growth Prospects in 2028+ are Underappreciate - Cantor Fitzgerald Reiterates Merck (MRK) at Overweight with $107 Price Target
Apr 1, 2022 12:48PM
Mar 31, 2022 12:42PM
Mar 31, 2022 06:23AM
Mar 29, 2022 05:54AM
Mar 24, 2022 12:08PM
Mar 23, 2022 09:44AM
Mar 17, 2022 10:55AM Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) Overwight, $10 PT, Sees Company's Bromodomain and Extra-Terminal Domain Inhibitors Programs are Underappreciated
Mar 16, 2022 07:12PM
Mar 10, 2022 11:05AM
Mar 8, 2022 05:58AM
Mar 7, 2022 07:59AM
Mar 7, 2022 07:36AM
Mar 4, 2022 06:36AM
Mar 3, 2022 02:53PM Cantor Fitzgerald Reiterates Hutchison China MediTech Ltd. (HCM) at Overweight, Believes HCM's Pipeline is Underappreciated
Mar 3, 2022 12:21PM

742 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All